FRAX® and its applications in health economics-Cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example

Bone

Volumn 47, Issue 2, 2010, Pages 430-437

  Strom O ^a,b   Borgstrom F ^a,b   Kleman, M ^a   McCloskey, E ^c   Oden A ^d   Johansson, H ^d   Kanis, J A ^d  

^a Medical Management Centre Karolinska Institutet ^*  (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NORTHERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Absolute risk; Fracture; Model; Osteoporosis

Indexed keywords

BAZEDOXIFENE; BONE DENSITY CONSERVATION AGENT; INDOLE DERIVATIVE;

ALGORITHM; ANALYTIC METHOD; ARTICLE; BONE DENSITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE MODEL; DRUG COST; DRUG EFFICACY; FRACTURE; FRAX; HEALTH ECONOMICS; HIGH RISK POPULATION; MORTALITY; OSTEOPOROSIS; RISK ASSESSMENT; THROMBOEMBOLISM; AGED; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; HUMAN; METHODOLOGY; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; SWEDEN;

AGED; AGED, 80 AND OVER; ALGORITHMS; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; FRACTURES, BONE; HEALTH CARE COSTS; HUMANS; INDOLES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY OF LIFE; RISK ASSESSMENT; SWEDEN;

EID: 77956011473     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.05.020     Document Type: Article

References (66)

1. Kanis J.A., Borgstrom F., De Laet C., et al. Assessment of fracture risk. Osteoporos. Int. 2005, 16:581-589.
2. Kanis J.A., Oden A., Johnell O., et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos. Int. 2007, 18:1033-1046.
3. TM and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 2008, 19:385-397.
4. McCloskey E.V., Johansson H., Oden A., et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy-additional results from a double-blind, placebo-controlled randomised study. Osteoporos. Int. 2009, 20:811-817.
5. Kanis J.A., Johansson H., Oden A., McCloskey E.V. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009, 44:1049-1054.
6. Kanis J.A., McCloskey E.V., Johansson H., Strom O., Borgstrom F., Oden A. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos. Int. 2008, 19:1395-1408. (Erratum published 2009 Osteoporos Int 1320, 1499-1502).
7. Kanis J.A., Burlet N., Cooper C., et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 2008, 19:399-428.
8. Siminoski K., Leslie W.D., Frame H., et al. Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J. Clin. Densitom. 2007, 10:120-123.
9. Tosteson A.N., Burge R.T., Marshall D.A., Lindsay R. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am. J. Manag. Care 2008, 14:605-615.
10. Dawson-Hughes B., Tosteson A.N., Melton L.J., et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos. Int. 2008, 19:449-458.
11. Kurth A.A., Pfeilschifter J. Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006. Orthopade 2007, 36:683-690. quiz 691.
12. Compston J., Cooper A., Cooper C., et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009, 62:105-108.
13. Clinician's guide to prevention and treatment of osteoporosis 2008, National Osteoporosis Foundation, Washington, DC, www.nof.org.
14. Silverman S.L., Christiansen C., Genant H.K., et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J. Bone Miner. Res. 2008, 23:1923-1934.
15. Borgström F., Ström O., Kleman M., et al. Cost-effectiveness of bazedoxifene incorporating the FRAX(r) algorithm in a European perspective. Osteoporos. Int. 2010, E-pub ahead of print.
16. Kanis J. on behalf of the World Health Organization Scientific Group 2008, WHO Collaborating Centre, University of Sheffield, UK, Assessment of osteoporosis at the primary health-care level. Technical Report.
17. Kanis J.A., Johnell O., De Laet C., Jonsson B., Oden A., Ogelsby A.K. International variations in hip fracture probabilities: implications for risk assessment. J. Bone Miner. Res. 2002, 17:1237-1244.
18. Strom O., Borgstrom F., Sen S.S., et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries-an economic evaluation based on the fracture intervention trial. Osteoporos. Int. 2007, 18:1047-1061.
19. Borgstrom F., Johnell O., Kanis J.A., Oden A., Sykes D., Jonsson B. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 2004, 22:1153-1165.
20. Borgstrom F., Jonsson B., Strom O., Kanis J.A. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos. Int. 2006, 17:1781-1793.
21. Kanis JA Borgstrom F., Johnell O., Jonsson B. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos. Int. 2004.
22. Kanis J., Brazier J., Stevenson M., Calvert W., Jones M.L. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol. Assess. 2002, 6:1-146.
23. Stevenson M., Lloyd Jones M., De Nigris E., Brewer N., Davis S., Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol. Assess. 2005, 9:1-160.
24. Cauley J.A., Thompson D.E., Ensrud K.C., Scott J.C., Black D. Risk of mortality following clinical fractures. Osteoporos. Int. 2000, 11:556-561.
25. Center J.R., Nguyen T.V., Schneider D., Sambrook P.N., Eisman J.A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999, 353:878-882.
26. Bliuc D., Nguyen N.D., Milch V.E., Nguyen T.V., Eisman J.A., Center J.R. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009, 301:513-521.
27. Poor G., Atkinson E.J., O'Fallon W.M., Melton L.J. Determinants of reduced survival following hip fractures in men. Clin. Orthop. 1995, 260-265.
28. Kanis J., Johnell O., Odén A., Laet C.D., Jonsson B., Oglesby A. Excess mortality after vertebral fracture 2002, WHO Collabortaing Centre for Metabolic Bone Diseases, Sheffield, UK.
29. Stevenson M., Davis S., Lloyd-Jones M., Beverley C. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol. Assess. 2007, 11:1-134.
30. McCloskey E., Johansson H., Oden A., Kanis J.A. Bazedoxifene reduces all clinical fractures and morphometric vertebral fractures in postmenopausal women at increased fracture risk assessed with FRAX(r). Osteoporos. Int. 2009, 20(Suppl 2):199-200.
31. Zethraeus N., Borgstrom F., Jonsson B., Kanis J. Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial. Int. J. Technol. Assess. Health Care 2005, 21:433-441.
32. Ström O., Coelho J., Borgstrom F., et al. Cost-effectiveness of bazedoxifene in the UK and Sweden incorporating the FRAX-algorithm Oral presentation (OC27) 2009, ECCEO, Athens.
33. Ström O., Borgstrom F., McCloskey E., Odén A., Johansson H., Kanis J. Cost-effectiveness of bazedoxifene in the US incorporating the FRAX(r) algorithm. J. Bone Miner. Res. 2009, 24(suppl. 1). http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx'aid=b141 6cf8-4c60-4fa9-a0c6-3b18f4b8719f.
34. Borgstrom F., Zethraeus N. Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective. Lakartidningen 2003, 100:36-40.
35. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J. Health Econ. 1997, 16:33-64.
36. Ekman M. (2002) Consumption and production by age in Sweden: Basic facts and health economic implications. In EFI SS (ed).
37. Johanesson M, Jonsson, B, Jonsson, L, Kobelt, G, Zethraeus, N. (2009) Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective? Office of Health Economics (OHE) No. 51 October.
38. (2003) Dental and Pharmaceutical Benefits Agency - General guidelines for economic evaluations from the Pharmaceutical Benefits Board. www.tlv.se.
39. Ström O, Borgstrom, F, Kleman, M, McCloskey, E, Odén, A, Johansson, H, Kanis, J. (2010) FRAX(r) and its applications in health economics - Cost-effectiveness and intervention thresholds. BONE In press.
40. Kanis J, McCloskey, E, Johansson, H, Strom, O, Borgstrom, F, Oden, A. (2008) Case finding for the management of osteoporosis with FRAX(tm) -Assessment and intervention thresholds for the UK. Osteoporos Int in press.
41. (2008) Osteoporosis: Clinical guideline for prevention and treatment. In. National Osteoporosis Guideline Group on behalf of the Bone Research Society, British Geriatrics Society, British Society of Rheumatology, Society of Endocrinology, British Orthopaedic Association, Primary Care Rheumatology Society, Osteoporosis 2000 and Osteoporosis Dorset.
42. van Staa T.P., Leufkens H.G., Abenhaim L., Zhang B., Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000, 39:1383-1389.
43. Kanis J.A., Johansson H., Johnell O., et al. Alcohol intake as a risk factor for fracture. Osteoporos. Int. 2005, 16:737-742.
44. Delmas P.D., Genant H.K., Crans G.G., et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003, 33:522-532.
45. Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women 2008, National Institute for Health and Clinical Excellence, London.
46. Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women 2008, National Institute for Health and Clinical Excellence, London.
47. Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP/EWP/552/95Rev.2 2006, Committee for Medicinal Products for Human Use (CHMP, London.
48. (1994) Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Division of Metabolism and Endocrine Drug Products. In. Food and Drug Administration, Rockville.
49. Saag K.G., Emkey R., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J. Med. 1998, 339:292-299.
50. Adachi J.D., Saag K.G., Delmas P.D., et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001, 44:202-211.
51. Reginster J., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. PG-83-91. Osteoporos. Int. 2000, 11:1.
52. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344:333-340.
53. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
54. Chapuy M.C., Arlot M.E., Delmas P.D., Meunier P.J. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994, 308:1081-1082.
55. Johansson H., Oden A., Johnell O., et al. Optimization of BMD measurements to identify high risk groups for treatment-a test analysis. J. Bone Miner. Res. 2004, 19:906-913.
56. Borgstrom F., Zethraeus N., Johnell O., et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos. Int. 2006, 17:637-650.
57. Zethraeus N., Strom O., Borgstrom F. What is the risk of institutionalization after hip fracture?. Osteoporos. Int. 2006, 17(Suppl 1):57-58.
58. Ström O., Borgstrom F., Zethraeus N., et al. Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop. 2008, 79:269-280.
59. Jonsson B., Christiansen C., Johnell O., Hedbrandt J., Karlsson G. Cost-effectiveness of fracture prevention in established osteoporosis. Scand. J. Rheumatol. Suppl. 1996, 103:30-38.
60. Stevenson M, Davis, S. (2006) Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide. In.
61. Kanis J.A., Oden A., Johnell O., Jonsson B., de Laet C., Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos. Int. 2001, 12:417-427.
62. Kanis J.A., Johnell O., Oden A., et al. The risk and burden of vertebral fractures in Sweden. Osteoporos. Int. 2004, 15:20-26.
63. Centre for Epidemiology at the National Board of Health and Welfare, Sweden.
64. Stadsledningskontoret. (2003) Stockholms stads budgetavräkning. In.
65. FASS för förskrivare. In.
66. Burstrom K., Johannesson M., Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual. Life Res. 2001, 10:621-635.